Hydrogenology
Hydrogenology editorial study record

A Case Report of Adjuvant Molecular Hydrogen Therapy in Refractory Rheumatoid Arthritis With Atlantoaxial Subluxation.

Ren YC, Lu JW, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC. · In Vivo. 2025;39:14166.

HumanOther formsPublished 2025
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Case report

Research topic

Musculoskeletal and pain research

Administration classification

Other forms

Study result signal

Indeterminate for molecular hydrogen.

Outcome type

Clinical course and immune biomarkers in a single patient.

Reported in the source

Methods at a glance

Population or model

An 85-year-old woman with rheumatoid arthritis, atlantoaxial subluxation, dialysis and multiple comorbidities.

Sample

1 patient.

Duration

Longitudinal follow-up described from 2023 onward.

Intervention

Oral molecular-hydrogen therapy as an adjunct to ongoing multidisciplinary care.

Hydrogen form

Hydrogen generated after ingestion of a capsule; not Brown's gas.

H₂ specification

A directly measured hydrogen dose or systemic concentration was not reported.

H₂ flow

Not applicable — oral product.

O₂ delivered with H₂

No oxygen was co-delivered.

Comparator

No control; before-and-after clinical course.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Hospital admissions, fatigue, clinical status and immune markers.

Reported result

The report describes fewer admissions, reduced fatigue and changes in selected immune measures during follow-up.

Results-extraction completeness

The full case report, timeline, measurements and concomitant care were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

A single complex case with extensive concurrent care cannot establish treatment efficacy or isolate hydrogen.

Applies directly to

This individual case only.

Preliminary appraisal framework

JBI Case Report Checklist — preliminary

Preliminary risk-of-bias status

Serious concerns

Appraisal rationale

No comparator and very high confounding by comorbidity, dialysis, medications and concurrent care.

Appraisal domains

Single selected case · Co-interventions were present · Follow-up described in the report · Several outcomes were clinician- or patient-reported · No prespecified analysis plan

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 41167690 · DOI: 10.21873/invivo.14166

Publisher access

Free full article in PubMed Central.

Extraction basis

PubMed record and PubMed Central full text; extraction checked 9 August 2026.

Record revision

2026-08-10